Financial Results for the fourth quarter and year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Smruthi Organics Ltd reported flat FY25 results with revenue from operations of Rs. 12,600.79 lakhs, slightly down 1.3% from Rs. 12,764.31 lakhs in FY24. Net profit stood at Rs. 356.29 lakhs vs Rs. 359.03 lakhs, a marginal 0.8% dip, with EPS at Rs. 3.11 (vs Rs. 3.14). Q4 showed a strong sequential recovery — revenue rose about 22% QoQ to Rs. 3,809.45 lakhs and net profit jumped around 51% to Rs. 223.01 lakhs. The board declared a dividend of Rs. 1.5 per share (15%) for FY25. Statutory auditor Gokhale & Sathe issued an unmodified opinion, with no exceptional items. Operating cashflow remained healthy at Rs. 997.62 lakhs, while capex of Rs. 1,151.50 lakhs was funded through higher borrowings.
Shareholders get a 15% dividend and steady profitability despite a slight top-line dip. The strong Q4 sequential rebound and clean audit are positive signals, though the modest full-year revenue decline and rising debt (D/E ~0.23) are points to watch. Overall, a stable but unspectacular year for retail investors.